HYPM.Y Stock Overview
Operates as a pharmaceutical company in Brazil. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Hypera S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R$2.88 |
| 52 Week High | R$7.65 |
| 52 Week Low | R$2.64 |
| Beta | 0.44 |
| 1 Month Change | -13.20% |
| 3 Month Change | -41.76% |
| 1 Year Change | -59.75% |
| 3 Year Change | -42.31% |
| 5 Year Change | -68.33% |
| Change since IPO | -80.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| HYPM.Y | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 5.2% | 1.3% | 0.6% |
| 1Y | -59.8% | 8.0% | 23.8% |
Return vs Industry: HYPM.Y underperformed the US Pharmaceuticals industry which returned 8.9% over the past year.
Return vs Market: HYPM.Y underperformed the US Market which returned 24.6% over the past year.
Price Volatility
| HYPM.Y volatility | |
|---|---|
| HYPM.Y Average Weekly Movement | 8.7% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HYPM.Y has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HYPM.Y's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 10,301 | Breno Pires de Oliveira | www.hypera.com.br |
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, Equilibrisse, balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum, and Torsilax brands; and over-the-counter drugs under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand.
Hypera S.A. Fundamentals Summary
| HYPM.Y fundamental statistics | |
|---|---|
| Market cap | US$1.86b |
| Earnings (TTM) | US$253.60m |
| Revenue (TTM) | US$1.26b |
7.3x
P/E Ratio1.5x
P/S RatioIs HYPM.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HYPM.Y income statement (TTM) | |
|---|---|
| Revenue | R$7.78b |
| Cost of Revenue | R$3.04b |
| Gross Profit | R$4.74b |
| Other Expenses | R$3.17b |
| Earnings | R$1.57b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.48 |
| Gross Margin | 60.95% |
| Net Profit Margin | 20.18% |
| Debt/Equity Ratio | 84.3% |
How did HYPM.Y perform over the long term?
See historical performance and comparisonDividends
6.8%
Current Dividend Yield28%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 21:39 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hypera S.A. is covered by 32 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andréa Aznar | BB Banco de Investimento S.A. |
| Georgia Jorge | BB Banco de Investimento S.A. |
| Robert Ford Aguilar | BofA Global Research |